TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9514186

Group type: EXPERIMENTAL
Intervention: MDL 100,240 (doses: 1.56 mg, 6.25 mg, 25 mg, 3.13 mg, 12.5 mg, 50 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MDL 100,240 (doses: 3.125 mg, 25 mg, 50 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MDL 100,240
Number of subjects: 8

Group type: COMPARATOR
Intervention: Exogenous angiotensin II challenge
Number of subjects: 8
Study: 7513406

Group type: EXPERIMENTAL
Intervention: Biphasic defibrillation waveform
Number of subjects: 30

Group type: COMPARATOR
Intervention: Monophasic defibrillation waveform
Number of subjects: 30
Study: 3198545

Group type: EXPERIMENTAL
Intervention: Videotape with behavior rehearsal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Videotape only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard safety program
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training
Number of subjects: 0
Study: 31843995

Group type: EXPERIMENTAL
Intervention: SUL-DUR (1 g/1 g intravenously every 6 hours for 7 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (intravenous every 6 hours for 7 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SUL-DUR with IMI background therapy
Number of subjects: 80
Study: 29978593

Group type: EXPERIMENTAL
Intervention: Patient-initiated follow up
Number of subjects: 156

Group type: COMPARATOR
Intervention: Hospital-based follow up
Number of subjects: 156
Study: 26370102

Group type: EXPERIMENTAL
Intervention: Taoist Qigong training for 1 month
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study: 25246392

Group type: EXPERIMENTAL
Intervention: Tedizolid 200 mg once daily for 6 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linezolid 600 mg twice daily for 10 days
Number of subjects: 0
Study: 22777222

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%/BPO 2.5% gel
Number of subjects: 337

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 337
Study: 20598271

Group type: EXPERIMENTAL
Intervention: Older adults with long preparatory interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older adults with short preparatory interval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Younger adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0
Study: 18052567

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 145
Study: 16354458

Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (ccHRT; Indivina, Orion Pharma, Finland)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (age-matched women from Finnish population health surveys)
Number of subjects: 0
Study: 12079031

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 111
Study: 10644486

Group type: EXPERIMENTAL
Intervention: Rectal pacing with 5-mA amplitude and 200-ms pulse width
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rectal pacing in study group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no pacing)
Number of subjects: 24
Study: 8777665

Group type: EXPERIMENTAL
Intervention: Warmed heel
Number of subjects: 57

Group type: COMPARATOR
Intervention: Unwarmed heel
Number of subjects: 57
Study: 1998863

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasonography
Number of subjects: 99

Group type: COMPARATOR
Intervention: Palpation of the liver
Number of subjects: 99

Group type: COMPARATOR
Intervention: Preoperative abdominal ultrasonography
Number of subjects: 99

Group type: COMPARATOR
Intervention: Computed tomography scanning
Number of subjects: 99
Study: 6398158

Group type: EXPERIMENTAL
Intervention: Clozic (100 mg/day)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clozic (300 mg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: D-penicillamine (500 mg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Aspirin (up to 3.6 g/day)
Number of subjects: 56
Study: 30861606

Group type: EXPERIMENTAL
Intervention: CLCA-ESD
Number of subjects: 50
Study: 30350779

Group type: EXPERIMENTAL
Intervention: Community-wide treatment (CWT) for 4 years
Number of subjects: 14620

Group type: EXPERIMENTAL
Intervention: School-based treatment (SBT) for 2 years followed by 2 years without treatment (holiday)
Number of subjects: 14620

Group type: EXPERIMENTAL
Intervention: 4 years of SBT
Number of subjects: 14620

Group type: EXPERIMENTAL
Intervention: 2 years of SBT combined with 2 years of treatment holiday
Number of subjects: 14620
Study: 26761518

Group type: EXPERIMENTAL
Intervention: Low-dose IL-12 (50 μg) with HIV MAG pDNA by IM-EP
Number of subjects: 62

Group type: COMPARATOR
Intervention: Any vaccine arm
Number of subjects: 62
Study: 24450538

Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg
Number of subjects: 383
Study: 22508813

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg two times per day)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study: 19464421

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 17251802

Group type: EXPERIMENTAL
Intervention: Lacrimal punctum occlusion (punctum plug in upper and lower puncta)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control eye (not occluded)
Number of subjects: 20
Study: 15970809

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate therapy until the onset of diuresis (urine output >100 mL/hr for 2 consecutive hours)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Magnesium sulfate therapy for 24 hours (control group)
Number of subjects: 98
Study: 11552905

Group type: COMPARATOR
Intervention: Proton pump inhibitor b.d. (omeprazole 20 mg or lansoprazole 30 mg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor b.d. (omeprazole 20 mg or lansoprazole 30 mg) plus bedtime H2-blocker
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Bedtime H2RA added to proton pump inhibitor b.d.
Number of subjects: 105
Study: 9314118

Group type: COMPARATOR
Intervention: Lamivudine (5 to 600 mg per day) for 4 weeks
Number of subjects: 17
Study: 8365298

Group type: EXPERIMENTAL
Intervention: albuterol by metered dose inhaler (0.4 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: albuterol by wet nebulizer (2.5 mg)
Number of subjects: 80
Study: 2427807

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 14
Study: 3076999

Group type: EXPERIMENTAL
Intervention: RE7 (rifampicin and ethambutol daily)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: RE3 (rifampicin and ethambutol thrice weekly)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: REZ3 (rifampicin, ethambutol, and pyrazinamide for the first 3 months)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: REPt3 (rifampicin, ethambutol, and prothionamide for the first 3 months)
Number of subjects: 501
Study: 30602406

Group type: EXPERIMENTAL
Intervention: Discrete choice experiment (DCE) methodology
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DCE attributes identified
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Refinements made to DCE
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Final planned DCE execution
Number of subjects: 10
Study: 28473924

Group type: EXPERIMENTAL
Intervention: Storytelling intervention (We Talk about Our Hypertension)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Didactic intervention
Number of subjects: 160
Study: 25496927

Group type: EXPERIMENTAL
Intervention: Sterile elastic exsanguination tourniquet
Number of subjects: 311

Group type: COMPARATOR
Intervention: Pneumatic tourniquet
Number of subjects: 311
Study: 23327355

Group type: COMPARATOR
Intervention: Supportive Listening (SL)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Pragmatic Rehabilitation (PR)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Number of subjects: 296
Study: 21659893

Group type: EXPERIMENTAL
Intervention: β-alanine (4 g·d in powdered capsule form)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 18076750

Group type: EXPERIMENTAL
Intervention: Concurrent smoking cessation treatment
Number of subjects: 462

Group type: COMPARATOR
Intervention: Delayed smoking cessation treatment
Number of subjects: 462
Study: 17069590

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy followed by surgery (CRT group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Surgery alone (Surgery group)
Number of subjects: 45
Study: 15228924

Group type: EXPERIMENTAL
Intervention: Intravenous heroin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 0
Study: 10924606

Group type: EXPERIMENTAL
Intervention: WBC-reduced platelet concentrates (PCs)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard platelet concentrates (S-PCs)
Number of subjects: 13
Study: 9051367

Group type: EXPERIMENTAL
Intervention: Bicultural community health worker (CHW) intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-CHW intervention
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Program completers
Number of subjects: 64
Study: 8112444

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3456079

Group type: EXPERIMENTAL
Intervention: Methotrexate (1000 mg per square meter) infused over 24 hours
Number of subjects: 108
Study: 30855231

Group type: EXPERIMENTAL
Intervention: HypoDetect (Hypoglycemia Detector) using logistic regression with cost-sensitive learning
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Baseline systems without cost-sensitive learning
Number of subjects: 3000
Study: 28903955

Group type: EXPERIMENTAL
Intervention: Rare meat (RM) cooked at 55°C for 5 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fully cooked meat (FCM) cooked at 90°C for 30 min
Number of subjects: 10
Study: 25727851

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: FeNO levels
Number of subjects: 11
Study: 23178661

Group type: EXPERIMENTAL
Intervention: Wuling capsule
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 21212667

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 18763030

Group type: EXPERIMENTAL
Intervention: Follicle rupture evident by transvaginal ultrasonography
Number of subjects: 417

Group type: COMPARATOR
Intervention: No follicle rupture evident
Number of subjects: 417
Study: 16968848

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment regimen
Number of subjects: 8831

Group type: COMPARATOR
Intervention: Atenolol-based treatment regimen
Number of subjects: 8831
Study: 12543279

Group type: EXPERIMENTAL
Intervention: Dawn-dusk simulation (DDS) light therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Dim red light (placebo)
Number of subjects: 13
Study: 11239099

Group type: EXPERIMENTAL
Intervention: Outpatient commitment with case management services and outpatient treatment
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Extended outpatient commitment
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Sustained outpatient commitment combined with intensive outpatient treatment
Number of subjects: 331

Group type: COMPARATOR
Intervention: Control group (no outpatient commitment)
Number of subjects: 331
Study: 9309626

Group type: EXPERIMENTAL
Intervention: E2 72
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: E2 144
Number of subjects: 6

Group type: COMPARATOR
Intervention: C 72
Number of subjects: 6
Study: 8312677

Group type: EXPERIMENTAL
Intervention: perindopril
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ketanserin
Number of subjects: 44
Study: 2906346

Group type: EXPERIMENTAL
Intervention: Triphasic combination of gestodene and ethinyl estradiol
Number of subjects: 2298

Group type: COMPARATOR
Intervention: Low-dose triphasic combination of levonorgestrel and ethinyl estradiol
Number of subjects: 2298
Study: 31771942

Group type: EXPERIMENTAL
Intervention: Aquamin (800 mg of calcium per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aquamin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calcium
Number of subjects: 30
Study: 28937546

Group type: EXPERIMENTAL
Intervention: Right Unilateral ECT (RUL)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Bifrontal ECT (BF)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Bitemporal ECT (BT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Cognitive outcomes
Number of subjects: 82
Study: 27942876

Group type: EXPERIMENTAL
Intervention: Total Extraperitoneal Repair (TEP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stoppa Repair
Number of subjects: 50
Study: 25733584

Group type: EXPERIMENTAL
Intervention: GMI-1070
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 23159276

Group type: EXPERIMENTAL
Intervention: fesoterodine (4 mg daily for 4 weeks with an optional increase to 8 mg)
Number of subjects: 963

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 963
Study: 21385509

Group type: EXPERIMENTAL
Intervention: Resveratrol (2 x 5 mg orally)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 18171453

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate, parent training programme
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate, parent support programme
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo medication, parent training
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo medication, parent support
Number of subjects: 16
Study: 17345818

Group type: EXPERIMENTAL
Intervention: Alendronate (Fosamax)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Calcium and Vitamin D
Number of subjects: 187

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 187
Study: 14629104

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with sodium porfimer administered 48 hours before photoradiation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proton pump inhibitors
Number of subjects: 0
Study: 10998949

Group type: EXPERIMENTAL
Intervention: Motivation-matched intervention involving personality-specific motivational and coping skills training
Number of subjects: 198

Group type: COMPARATOR
Intervention: Motivational control intervention involving a motivational film and a supportive discussion with a therapist
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Motivation-mismatched intervention targeting a theoretically different personality profile
Number of subjects: 198
Study: 8869535

Group type: EXPERIMENTAL
Intervention: Semipermeable skin dressing (SPD) applied to the chest, abdomen, and back.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no dressing applied).
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Semipermeable skin dressing (SPD).
Number of subjects: 39
Study: 1798594

Group type: EXPERIMENTAL
Intervention: Fish protein supplementation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 19
Study: 6134535

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.03 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.057 mg kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pancuronium 0.042 mg kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pancuronium 0.08 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 40
Study: 31820032

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) in ICUs with low prevalence of antibiotic resistance
Number of subjects: 3

Group type: COMPARATOR
Intervention: Selective decontamination of the digestive tract (SDD) in ICUs with moderate-to-high prevalence of antibiotic resistance
Number of subjects: 3
Study: 30545718

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy with autoarterial remodeling of bifurcation of the common carotid artery (ARBCCA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Classic carotid endarterectomy with xenopericardial patch closure
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (ARBCCA and classic CEA)
Number of subjects: 200
Study: 28988232

Group type: EXPERIMENTAL
Intervention: CVVHD-HCO
Number of subjects: 30

Group type: COMPARATOR
Intervention: CVVHD-STD
Number of subjects: 30
Study: 25738786

Group type: EXPERIMENTAL
Intervention: Warming mattress
Number of subjects: 484

Group type: COMPARATOR
Intervention: Standard method of warming (heat-retaining caps, warmed intravenous and irrigation fluids, and warmed blankets)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Standard method of warming
Number of subjects: 484
Study: 23939292

Group type: EXPERIMENTAL
Intervention: Lotrafilcon B silicone hydrogel lenses (daily wear, monthly replacement)
Number of subjects: 240
Study: 21320316

Group type: EXPERIMENTAL
Intervention: Group A - informed their drinking will be assessed at baseline and again in one month (as in a cohort study design)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group B - told the study is an intervention trial and they are in the control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group C - told the study is an intervention trial and they are in the intervention group
Number of subjects: 0
Study: 19927175

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 68

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 68
Study: 17237662

Group type: EXPERIMENTAL
Intervention: IA CRH (10 microg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: IA CRH (10 microg) + naloxone (0.12 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: IA saline (isotonic) + IV CRH (10 microg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: IV saline
Number of subjects: 51
Study: 15566918

Group type: EXPERIMENTAL
Intervention: Azithromycin therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study: 11681501

Group type: EXPERIMENTAL
Intervention: indomethacin/gentamicin eyedrops
Number of subjects: 123

Group type: COMPARATOR
Intervention: gentamicin alone
Number of subjects: 123
Study: 9761520

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rhEPO)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not treated with rhEPO)
Number of subjects: 102
Study: 8659195

Group type: EXPERIMENTAL
Intervention: Running or swimming therapy (according to the stamina principle)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nifedipine therapy (40‐60 mg/d)
Number of subjects: 40
Study: 2258250

Group type: EXPERIMENTAL
Intervention: Droxicam (20 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Piroxicam (20 mg/day)
Number of subjects: 30
Study: 6947988

Group type: EXPERIMENTAL
Intervention: 0.035% alexidine mouthrinse
Number of subjects: 22

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthrinse
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: In vitro study with 0.035% alexidine
Number of subjects: 22

Group type: COMPARATOR
Intervention: In vitro study with 0.2% chlorhexidine
Number of subjects: 22
Study: 31910861

Group type: EXPERIMENTAL
Intervention: SWATs (Studies Within A Trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 29685813

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (TOBI 300 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 27987240

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5/10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study: 26278075

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication during scenario encoding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sober participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants told they were drinking alcohol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral details
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central details
Number of subjects: 0
Study: 24691799

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg and Fenofibrate 145 mg (simultaneous dosing)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg and Fenofibrate 145 mg (staggered dosing)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Simvastatin only (evening)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Simvastatin and Fenofibrate (both in evening)
Number of subjects: 85
Study: 22978099

Group type: EXPERIMENTAL
Intervention: Tiaomian No. 3 (TM3)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Active immunotherapy using lymphocytes of spouses (Control)
Number of subjects: 61
Study: 20089449

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 94370

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 94370
Study: 17204716

Group type: EXPERIMENTAL
Intervention: CT cancer screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PET/CT cancer screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-body PET/CT for diagnosing, staging, and restaging cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-body PET/CT for surveillance of selected groups of patients
Number of subjects: 0
Study: 15604959

Group type: EXPERIMENTAL
Intervention: Early lymphoscintigraphy (15 minutes to 4 hours after radionuclide injection)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Delayed lymphoscintigraphy (18‐24 hours after radionuclide injection)
Number of subjects: 15
Study: 12121799

Group type: EXPERIMENTAL
Intervention: TLC-PA (telephone-linked communication promoting moderate-intensity physical activity)
Number of subjects: 298

Group type: COMPARATOR
Intervention: TLC-Eat (automated intervention promoting healthy eating)
Number of subjects: 298